# AMG 529 First in Human Study

> **NCT03170193** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 48 (actual)

## Conditions studied

- Cardiovascular

## Interventions

- **DRUG:** AMG 529
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03170193
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2017-11-17
- **Final completion:** 2017-11-17
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03170193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03170193, "AMG 529 First in Human Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03170193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*